BioSpace News Archive

Data from two first-ever studies reveal extreme clinical, emotional, social, and financial burdens on patients with pediatric congenital athymia and their families, and extraordinary costs of supportive care to healthcare systems.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2021.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies today announced the financial results for its fiscal second quarter ending June 30, 2021, and provided a corporate update.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today the recruitment of stem cell pioneer and key opinion leader Francisco Silva to the Company’s Scientific Advisory Board.

Aria Pharmaceuticals, a drug discovery and development company focused on bringing first-in-class small molecules to market, today announced that two novel candidates for the potential treatment of idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies.

Johnson & Johnson (NYSE: JNJ) will participate in the Cantor Virtual Global Healthcare Conference on Tuesday, September 28th.

Antigens are chemical substances that are capable of triggering an immune response in the host body by initiating antibodies production that helps resist bacterial infections.

Biotechnological products, which include ointments, drugs, and lotions, are pharmaceuticals contract manufacturing products.

Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced the pricing of an underwritten public offering of 5,000,000 shares of common stock of the Company, at a price of $3.00 per share for total gross proceeds to the Company of approximately $15 million.